Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ACADIA Pharmaceuticals Inc. (ACAD) vs Xenon Pharmaceuticals Inc. (XENE)

ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. are both Biotechnology companies. ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. are of similar size ($3.8B and $3.7B). Xenon Pharmaceuticals Inc. has negative trailing earnings, so its P/E is not meaningful; ACADIA Pharmaceuticals Inc. trades at 9.2×. ACADIA Pharmaceuticals Inc. grew revenue faster over the last twelve months: 11.8% against −8.15%. ACADIA Pharmaceuticals Inc. has the higher net margin (33.4% vs 0.00%) and the higher return on invested capital (15.4% vs −88.5%). Across the 17 metrics below, ACADIA Pharmaceuticals Inc. leads on 15 and Xenon Pharmaceuticals Inc. on 2.

Valuation

Metric ACAD XENE Biotechnology median
P/E 9.19 n/m 7.88
P/S 3.12 217.29 11.47
P/B 2.72 2.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 27.47 n/m 0.74
EV/Sales 2.32 162.98 10.73
Earnings yield 10.88% (12.83%) (28.84%)
Free cash flow yield (1.47%) (9.20%) (23.03%)

Profitability

Metric ACAD XENE Biotechnology median
Gross margin 91.13% 28.40% 65.16%
Operating margin 7.59% 0.00% 0.00%
Net margin 33.42% 0.00% 0.00%
Free cash flow margin 12.79% 0.00% 0.00%
Return on equity 35.74% (43.62%) (57.72%)
Return on assets 25.64% (41.54%) (49.22%)
Return on invested capital 15.42% (88.54%) 0.00%

Growth

Metric ACAD XENE Biotechnology median
Revenue growth (TTM) 11.75% (8.15%) 5.64%
EPS growth (last fiscal year) 69.12% (44.85%) —
Revenue growth, 5-year CAGR 19.39% 89.00% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACAD XENE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.39 21.02 4.73
Net debt to EBITDA (7.37) 1.48 0.96

Dividend

Metric ACAD XENE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ACAD XENE Biotechnology median
Market cap 3.83b 3.73b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack